Volume 151, Issue 1, Pages 97-109.e4 (July 2016) Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune- Mediated Diseases: A Systematic Review and Meta-analysis Edward Shelton, David Laharie, Frank I. Scott, Ronac Mamtani, James D. Lewis, Jean-Frederic Colombel, Ashwin N. Ananthakrishnan Gastroenterology Volume 151, Issue 1, Pages 97-109.e4 (July 2016) DOI: 10.1053/j.gastro.2016.03.037 Copyright © 2016 AGA Institute Terms and Conditions
Figure 1 Flowchart of the literature search. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Figure 2 Forest plot of risk of recurrence of cancer or development of new primary by type of immunosuppression in individuals with a prior history of cancer. NMSC, nonmelanoma skin cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Figure 3 Forest plot of risk of new primary cancer by type of immunosuppression in individuals with a prior history of cancer. NMSC, nonmelanoma skin cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Figure 4 Forest plot of risk of recurrence of prior cancer by type of immunosuppression in individuals with a prior history of cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Figure 5 Incident rate differences between no immunosuppression, conventional immunomodulator, and anti-TNF therapy. (A) Conventional IMM vs anti-TNF therapy. (B) Conventional IMM vs no IS. (C) Anti-TNF vs no IS. NMSC, nonmelanoma skin cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Supplementary Figure 1 Risk of recurrence of cancer or development of a new primary by type of immunosuppression in individuals with inflammatory bowel disease and a prior history of cancer. NMSC, nonmelanoma skin cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Supplementary Figure 2 Risk of recurrence of cancer or development of a new primary by type of immunosuppression in individuals with rheumatoid arthritis and a prior history of cancer. NMSC, nonmelanoma skin cancer. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions
Supplementary Figure 3 Egger plot for assessment of publication bias. SND, standard error. Gastroenterology 2016 151, 97-109.e4DOI: (10.1053/j.gastro.2016.03.037) Copyright © 2016 AGA Institute Terms and Conditions